Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
encoberminogene rezmadenovec
- Development stage
- Phase 3
- Lead developer
- XyloCor Therapeutics
- Modality
- Gene Therapies
- Administration
- Intramuscular
01
Overview
Encoberminogene rezmadenovec (XC001) is an investigational adenoviral vector-based gene therapy developed by XyloCor Therapeutics. It consists of a recombinant adenoviral vector encoding the vascular endothelial growth factor (VEGF) gene. The therapy is designed to promote therapeutic angiogenesis — the growth of new blood vessels — within the heart to reduce cardiac ischemia and improve blood flow. It is primarily being developed for patients with refractory angina pectoris and coronary artery disease who have limited treatment options, as well as an adjunct for patients with reduced left ventricular function undergoing coronary artery bypass graft (CABG) surgery.
- Brand names
- XyloCore
- Other names
- encoberminogene rezmadenovecXC001XC-001XC 001
02
Targets
HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)
Beyond the preview
Go deeper on encoberminogene rezmadenovec.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on encoberminogene rezmadenovec.